Corient Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.54M | Buy |
5,448
+125
| +2% | +$35.2K | 0.11% | 157 |
|
|
2022
Q2 | $1.5M | Buy |
5,323
+695
| +15% | +$196K | 0.11% | 165 |
|
|
2022
Q1 | $1.21M | Buy |
4,628
+769
| +20% | +$201K | 0.08% | 216 |
|
|
2021
Q4 | $848K | Buy |
3,859
+694
| +22% | +$153K | 0.06% | 262 |
|
|
2021
Q3 | $574K | Sell |
3,165
-462
| -13% | -$83.8K | 0.04% | 331 |
|
|
2021
Q2 | $732K | Buy |
3,627
+191
| +6% | +$38.5K | 0.05% | 272 |
|
|
2021
Q1 | $738K | Buy |
3,436
+142
| +4% | +$30.5K | 0.06% | 244 |
|
|
2020
Q4 | $779K | Buy |
3,294
+242
| +8% | +$57.2K | 0.08% | 206 |
|
|
2020
Q3 | $830K | Sell |
3,052
-227
| -7% | -$61.7K | 0.1% | 183 |
|
|
2020
Q2 | $952K | Buy |
3,279
+258
| +9% | +$74.9K | 0.12% | 165 |
|
|
2020
Q1 | $719K | Buy |
3,021
+358
| +13% | +$85.2K | 0.11% | 158 |
|
|
2019
Q4 | $583K | Buy |
2,663
+63
| +2% | +$13.8K | 0.07% | 257 |
|
|
2019
Q3 | $441K | Buy |
2,600
+542
| +26% | +$91.9K | 0.06% | 279 |
|
|
2019
Q2 | $377K | Sell |
2,058
-601
| -23% | -$110K | 0.06% | 275 |
|
|
2019
Q1 | $489K | Buy |
2,659
+1,260
| +90% | +$232K | 0.08% | 222 |
|
|
2018
Q4 | $232K | Buy |
+1,399
| New | +$232K | 0.04% | 285 |
|